MABEXPRESS Trademark

Trademark Overview

On Tuesday, June 20, 2023, a trademark application was filed for MABEXPRESS with the United States Patent and Trademark Office. The USPTO has given the MABEXPRESS trademark a serial number of 98050400. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Monday, September 9, 2024. This trademark is owned by Merck KGaA. The MABEXPRESS trademark is filed in the Treatment & Processing of Materials Services and Computer & Software Services & Scientific Services categories with the following description:

Custom manufacture of biopharmaceuticals; consultancy relating to biopharmaceutical manufacturing; consultancy relating to the manufacturing of therapeutics; custom biopharmaceutical drug manufacturing services

Scientific laboratory services relating to the production of monoclonal antibodies; product development services in the nature of biodevelopment services relating to the production of monoclonal antibodies; consultancy relating to biopharmaceutical research and development; biopharmaceutical drug development services; conducting of quality control tests for others; quality control services for others; quality assurance services in the field of biopharmaceuticals; testing, analysis and validation of biopharmaceuticals related to the development and production of monoclonal antibodies; research and development of therapeutics and consultancy related thereto
mabexpress

General Information

Serial Number98050400
Word MarkMABEXPRESS
Filing DateTuesday, June 20, 2023
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateMonday, September 9, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesCustom manufacture of biopharmaceuticals; consultancy relating to biopharmaceutical manufacturing; consultancy relating to the manufacturing of therapeutics; custom biopharmaceutical drug manufacturing services
Goods and ServicesScientific laboratory services relating to the production of monoclonal antibodies; product development services in the nature of biodevelopment services relating to the production of monoclonal antibodies; consultancy relating to biopharmaceutical research and development; biopharmaceutical drug development services; conducting of quality control tests for others; quality control services for others; quality assurance services in the field of biopharmaceuticals; testing, analysis and validation of biopharmaceuticals related to the development and production of monoclonal antibodies; research and development of therapeutics and consultancy related thereto

Classification Information

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateSunday, July 23, 2023
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSunday, July 23, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMerck KGaA
Party Type10 - Original Applicant
Legal Entity Type99 - Other
Address64293 Darmstadt F128/002
DE

Trademark Events

Event DateEvent Description
Friday, June 23, 2023NEW APPLICATION ENTERED
Sunday, July 23, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 21, 2023ASSIGNED TO EXAMINER
Friday, January 19, 2024NON-FINAL ACTION WRITTEN
Friday, January 19, 2024NON-FINAL ACTION E-MAILED
Friday, January 19, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, April 15, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, September 9, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 9, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, September 9, 2024ASSIGNED TO LIE

Related Keywords

mabexpress services development relating biopharmaceutical consultancy monoclonal biopharmaceuticals quality antibodies production